Sequana Medical Secures €24M to Transform Fluid Overload Treatment and Patient Care

Sequana Medical NV is thrilled to announce a successful funding round in which the company raised €24,000,000 to further its groundbreaking work in addressing drug-resistant fluid overload—a severe and frequent complication afflicting patients with liver disease, heart failure, and cancer. As a pioneer in the field, Sequana Medical has dedicated itself to finding innovative solutions for patients suffering from this debilitating condition, which can lead to an accumulation of up to 15 liters of extra fluid and result in increased mortality, repeated hospitalizations, severe pain, compromised breathing, and restricted mobility. This significant injection of capital will accelerate the development and broader adoption of Sequana Medical’s proprietary approaches, alfapump® and DSR®, which work harmoniously with the body to safely remove excess fluid, thereby enhancing patients’ quality of life and reducing overall healthcare costs. With this new funding, the company is poised to expand its clinical trials, enhance production capabilities, and scale up marketing efforts to reach a larger patient community in need of effective treatment alternatives when traditional medicines fall short. Headquartered in Ghent, Belgium, and listed on Euronext Brussels (Ticker: SEQUA.BR), Sequana Medical stands at the forefront of medical innovation, committed to transforming the treatment landscape for those battling fluid overload. The dedication and expertise of the Sequana Medical team, combined with the fresh capital, signal a promising future for the company and the millions of patients who will benefit from its cutting-edge therapies. For further details about Sequana Medical and its revolutionary approaches, please visit www.sequanamedical.com.